In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Cardiff Oncology (CRDF – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $1.77.
Catanzaro covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Gilead Sciences, and Nurix Therapeutics. According to TipRanks, Catanzaro has an average return of 12.1% and a 43.34% success rate on recommended stocks.
Cardiff Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.79 and a one-year low of $0.94. Currently, Cardiff Oncology has an average volume of 193K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cardiff Oncology (CRDF) Company Description:
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
Read More on CRDF:
- Cardiff Oncology Reports Progress in Colorectal Cancer Trials
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- CRDF Earnings this Week: How Will it Perform?
